Arrowhead Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals, Inc., including shares issuable upon warrant exercise.
NASDAQ
Vanguard Portfolio Management has reported a 4.53% stake in Arrowhead Pharmaceuticals Inc., holding over 6.38 million shares.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 5.2% in Arrowhead Pharmaceuticals Inc. as of March 31, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.05% of Arrowhead Pharmaceuticals Inc.'s common stock as of March 31, 2026.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of 5.19% of Arrowhead Pharmaceuticals Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group filed an amended Schedule 13G for Arrowhead Pharmaceuticals Inc., reporting 0% beneficial ownership following an internal realignment.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Stake in Arrowhead Pharma to 15%
BlackRock, Inc. has increased its beneficial ownership in Arrowhead Pharmaceuticals Inc. to 15.0% of common stock, holding over 20 million shares.
NASDAQ
Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 8.3% in Arrowhead Pharmaceuticals, Inc., holding over 11.5 million shares.
NASDAQ
State Street Corporation has reported a 4.6% beneficial ownership stake in Arrowhead Pharmaceuticals Inc., holding over 6.3 million common shares.
NASDAQ
The Vanguard Group has filed an updated Schedule 13G, reporting a continued beneficial ownership of 11.24% in Arrowhead Pharmaceuticals Inc.
NASDAQ
State Street Corporation has filed a Schedule 13G, revealing a 5.1% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Amends Stake in Arrowhead Pharmaceuticals, Disclosing 13.8% Beneficial Ownership
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 13.8% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have disclosed a 9.6% beneficial ownership stake in Arrowhead Pharmaceuticals, Inc., including shares from warrant exercises.
NASDAQ
State Street Corporation has filed a Schedule 13G, reporting a passive beneficial ownership of 4.8% in Arrowhead Pharmaceuticals Inc.'s common stock as of December 31, 2024.